EMH Schweizerischer Ärzteverlag AG
Farnsburgerstrasse 8
CH-4132 Muttenz
+41 (0)61 467 85 44
support@swisshealthweb.ch
www.swisshealthweb.ch
Published on 01.09.2021
Three healthy young males who developed systemic symptoms closely following the second dose of Moderna.
Male 12–29 years old | 40.6 cases /1'000'000 second dose |
12–17 years old | 62.8 cases /1'000'000 second dose |
18–24 years old | 50.4 cases /1'000'000 second dose |
Male >30 years old | 2.4 cases /1'000'000 second dose |
Female 12–29 years old | 4.2 cases /1'000'000 second dose |
Females >30 years old | 1 case /1'000'000 second dose |
– | “Low-risk”: absence of clinical HF or low BP, preserved LVEF (>50%) and absence of arrhythmias. | |
– | “Intermediate-risk”: | |
a. | Mild HF signs/symptoms, mildly decreased LVEF (41–49%) and presence of arrhythmias. | |
b. | HF symptoms, moderately decreased LVEF (30–40%) and absence of arrhythmias. | |
– | “High-risk”: | |
a. | HF symptoms, moderately decreased LVEF (30–40%) and presence of arrhythmias. | |
b. | Cardiogenic shock, severely reduced LVEF (<30%) with or without arrhythmias. |
Published under the copyright license.
"Attribution - Non-Commercial - NoDerivatives 4.0"
No commercial reuse without permission.
See: emh.ch/en/emh/rights-and-licences/